Table 1. Major characteristics of the included studies in this meta-analysis.
| No. | Study ID | Country | Types of subjects | Number of Behçet's disease patients (number of female) |
Mean age/range of Behçet's disease patients (years) | Disease duration | Number of controls (number of female) | Control type | Mean age/range of control (years) | Types of tested aPLs (isotype); cut-offs |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zivkovic 2011 |
Serbia | Adult | 11 (3) | 34.6 | NR | 11 (NR) | Healthy | NR | aCL (IgG, IgM, IgA); ≥ 10.0 GPL / MPL |
| 2 | EL-Nakeeb 2006 |
Egypt | Adult | 25 (12) | 36.8 ± 5.7 | NR | 25 (17) | Subjects with rheumatic diseases without thrombosis; osteoarthritis (n = 10), rheumatoid arthritis (n = 9), psoriatic arthritis, (n = 3) and fibromyalgia (n = 3) |
39.0 ± 4.2 | aCL (IgG, IgM, IgA); NR, LA |
| 3 | Musabak 2005 |
Turkey | Adult | 33 (5) | 21–52 | 0–28 | 20 (3) | Healthy | 21–48 | aCL (IgG, IgM); ≥ 12 GPL and ≥ 13.0 MPL |
| 4 | Rajaee 2004 |
Iran | Adult | G1: 40 (29) G2: 40 (24) |
G1: 36.12 ± 7.83 G2: 30.65 ± 7.91 |
G1: 1–25 G2: 1–11 |
80 (NR) | Healthy | NR | aCL (IgG); ≥ 10.0 GPL |
| 5 | Espinosa 2002 |
Spain | Adult | 38 (17) | 27.0 ± 12.0 | NR | 100 (54) | Healthy | 41.0 ± 18.0 | aCL (IgG, IgM); NR, LA |
| 6 | El-Ageb 2002 |
Oman | Adult | 34 (18) | 32.8 ± 9.8 | 6.4 ± 3.2 | 27 (13) | Healthy | 26.2 ± 8.3 | aCL (IgG, IgM); ≥ 15.0 GPL / 12.5 MPL; anti-β2-GPI |
| 7 | Kang 1998 |
Korea | Adult | 47 (26) | 21–61 | 1–20 | 20 (NR) | Healthy | NR | aCL (IgG, IgM); ≥ 10 GPL / MPL |
| 8 | Hughes 1998 |
UK | Adult | 18 (NR) | NR | NR | 116 (NR) | Healthy | NR | aCL (IgG, IgM, IgA); NR |
| 9 | Ji 1992 |
Korea | Adult | 68 (38) | NR | NR | 20 (NR) | Healthy | NR | aCL (IgG, IgM); NR |
| 10 | Bergman 1990 |
Israel | Adult | 26 (6) | 20–68 | 1–28 | 200 (NR) | Healthy | NR | aCL (IgG, IgM); NR |
aCL: anticardiolipin; anti-β2-GPI: anti-β2-glycoprotein I; LA: lupus anticoagulant; aPT: antiprothrombin; aPI: antiphosphatidylinositol; aPC: antiphosphatidylcholine; aPS: antiphosphatidylserine; aPC: antiphosphatidylcholine; aPE: antiphosphatidylethanolamine; KCT: kaolin clotting time; OD: optical density; SD: standard deviation; NR: not reported.